<abstract xmlns="http://www.w3.org/1999/xhtml"><p> Olaparib is a potent oral inhibitor of PARP 1 &amp; 2 with biological activity in various solid tumours for patients with germline and/or sporadic BRCA mutations. The aim of this review is to present the results of the various studies which show Olaparib’s efficacy in ovarian cancer</p></abstract>

Olaparib is a potent oral inhibitor of PARP 1 & 2 with biological activity in various solid tumours for patients with germline and/or sporadic BRCA mutations. The aim of this review is to present the results of the various studies which show Olaparib’s efficacy in ovarian cancer

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer

2nd Oncology Dpt, Cancer Hospital of Kifisia “Oi Agioi Anargiroi”

Oncology Dpt., Department of Clinical Therapeutics at “Alexandra” Hospital, Athens

Director, 2nd Oncology Dpt, Cancer Hospital of Kifisia “Oi Agioi Anargiroi”

Forum of Clinical Oncology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

{"article-title":"OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer"}

Olaparib is a potent oral inhibitor of PARP 1 & 2 with biological activity in various solid tumours for patients with germline and/or sporadic BRCA mutations....

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer

Publicado en línea: 17 dic 2015

Páginas: 1 - 7

Recibido: 18 sept 2015

Aceptado: 30 sept 2015

DOI: https://doi.org/10.1515/fco-2015-0014

Palabras clave
PARP-inhibitors, Olaparib, Ovarian Cancer

© 2015

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer

Publicado en línea: 17 dic 2015

Páginas: 1 - 7

Recibido: 18 sept 2015

Aceptado: 30 sept 2015

DOI: https://doi.org/10.1515/fco-2015-0014

Palabras clavePARP-inhibitors, Olaparib, Ovarian Cancer

© 2015

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Palabras clave
PARP-inhibitors, Olaparib, Ovarian Cancer